Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

General Mills Recalls Flour After E. coli Outbreak

XTALKS VITALS NEWS

Flour

Consumers are being warned by both the FDA and the CDC not to consume any raw products containing flour, including cookie dough and cake batter.

Tweetables from this article:

Tweet: General Mills recalls more batches of #flour after E. coli outbreak http://ctt.ec/9J32Y+General Mills recalls more batches of flour after E. coli outbreak.

Tweet: CDC: 42 individuals across 21 states have been become ill as a result of contaminated flour http://ctt.ec/JnNmB+CDC: 42 individuals across 21 states have been become ill as a result of contaminated flour.

Share this!

July 5, 2016 | by Sarah Massey, M.Sc.

General Mills is recalling more batches of its flour after a multi-state outbreak of E. coli was linked to some of its products. The list of recalled products includes those branded as Gold Medal flour, Wondra flour and Signature Kitchens flour.

The newest update on the recall now includes batches prepared in the fall of 2015, which some consumers may still have in their pantry. The catalyst for the recall expansion was a new case of foodborne illness which “appears to have stemmed from the consumption of raw dough or batter linked to flour produced last fall.”

According to the Centers for Disease Control and Prevention (CDC), 42 individuals across 21 states have been become ill as a result of exposure to the contaminated flour. The flour has been found to contain Shiga toxin-producing E. coli (STEC) O121, and 11 people have been hospitalized due to the infection.



A type of kidney failure known as hemolytic uremic syndrome has so far not been developed in any of the affected individuals, and no illness-related deaths have been reported. Four new cases of the illness were identified in the month of June alone, and the STEC O121 bacterial strain has been isolated from flour samples collected from the homes of two ill people.

“In late June 2016, the [U.S. Food and Drug Administration (FDA)] isolated STEC O121 from samples of General Mills flour collected from the homes of ill people in Arizona and Oklahoma,” said the CDC. “The flour collected in Oklahoma was not included in the initial General Mills recall. In response to these laboratory findings, on July 1, 2016, General Mills expanded the recall to include additional lots of flour under the same brands from the initial recall.”

Consumers are being warned by both the FDA and the CDC not to consume any raw products containing flour, including cookie dough and cake batter. Baking, frying and boiling are all effective methods to kill the STEC O121 pathogen, however the affected batches of flour should be discarded.


Keywords: FDA, Recall, Foodborne Illness


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.